Summary: Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty (NASDAQ: LGVN) Longeveron Inc. a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today the completion of the Company’s Phase 2b clinical study of Lomecel-B infusion for Aging Frailty subjects. Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell product. “Completion of our Phase 2b clinical study of Lomecel-B Infusion to treat Aging Frailty marks a major milestone for the Company,” commented, Geoff Green, Chief Executive Officer of Longeveron. “We are grateful to the exceptional clinical trial sites, our partner the National Institute on Aging, and of course the subjects for their participation in this study. We are committed to developing safe and effective cell therapies for chronic aging-related diseases and life-threatening conditions, and we look forward to sharing the trial data later this year.” Aging Frailty is a life-threatening geriatric condition affecting approximately 15% of Americans over the age of 65, or 8.1 million individuals. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome, and hypoplastic left heart syndrome. Longeveron’s Aging Frailty clinical research program is one of the most extensive in the world. www.longeveron.com https://www.youtube.com/watch?v=QgCd2mqqTmg&t=4s GreenStockNews.com is an Internet-based publishing platform . Green Stock News for the New Gren Economy https://www.greenstocknews.com
